Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/Ii Using Response Adapted Involved Site Radiotherapy in Combination With Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and Response Adapted Involved-Site Radiotherapy): A Study Protocol for a Single-Arm, Non-Randomized, Open, National, Multi-Center Phase II Trial
Trials - United Kingdom
doi 10.1186/s13063-019-3614-y
Full Text
Open PDFAbstract
Available in full text
Date
August 30, 2019
Authors
Publisher
Springer Science and Business Media LLC